Literature DB >> 22222257

Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population.

K G Au Eong1, E W Chan, N Luo, S H Wong, N W H Tan, T H Lim, A M Wagle.   

Abstract

BACKGROUND/AIMS: Utility values of age-related macular degeneration (AMD) in Asian patients are unknown. This study aims to assess utility values and construct validity of the EuroQOL-5D (EQ-5D), time trade-off (TTO), and standard gamble (SG) instruments in the Singapore multi-ethnic AMD population.
METHODS: Cross-sectional, two-centre, institution-based study. Visual acuity (VA), clinical AMD severity, and utility scores on the EQ-5D, TTO, and SG were obtained from 338 AMD patients. VA was analysed in terms of the better-seeing eye (BEVA), worse-seeing eye (WEVA), and weighted average of both eyes (WVA). We evaluated SG on the perfect health-death (SG(death)) and binocular perfect vision-binocular blindness (SG(blindness)) scales. Construct validity was determined by testing a priorihypotheses relating the EQ-5D, TTO, and SG utility scores to VA and clinical AMD severity.
RESULTS: The mean utilities on the EQ-5D, TTO, SG(death), and SG(blindness) were 0.89, 0.81, 0.86, and 0.90, respectively. EQ-5D scores correlated weakly with BEVA, WEVA, and WVA (Pearson's correlation coefficients -0.291, -0.247, and -0.305 respectively, P<0.001 for all). SG(death) and SG(blindness) demonstrated no correlation with BEVA, WEVA, or WVA (Pearson's correlation coefficients, range -0.06 to -0.125). TTO showed weak association only with WEVA and WVA (correlation coefficients -0.237, -0.228, P<0.0001), but not with BEVA (correlation coefficient -0.161). Clinical AMD severity correlated with EQ-5D and SG(death), but not with TTO and SG(blindness) (P=0.004, 0.002, 0.235, and 0.069, respectively).
CONCLUSIONS: AMD has a negative impact on utilities, although utility scores were high compared with Western cohorts. EQ-5D, TTO, and SG showed suboptimal construct validity, suggesting that health status utilities may not be sufficiently robust for cost-utility analyses in this population.

Entities:  

Mesh:

Year:  2012        PMID: 22222257      PMCID: PMC3298978          DOI: 10.1038/eye.2011.218

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  42 in total

1.  Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration.

Authors:  Melissa M Brown; Gary C Brown; Sanjay Sharma; Jennifer Landy; Jeff Bakal
Journal:  Arch Ophthalmol       Date:  2002-04

2.  Validity and reliability of the EQ-5D self-report questionnaire in English-speaking Asian patients with rheumatic diseases in Singapore.

Authors:  N Luo; L H Chew; K Y Fong; D R Koh; S C Ng; K H Yoon; S Vasoo; S C Li; J Thumboo
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

3.  The elderly who live alone in the United States: historical perspectives on household change.

Authors:  E A Kramarow
Journal:  Demography       Date:  1995-08

4.  The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER.

Authors:  Aimee Teo Broman; Beatriz Munoz; Jorge Rodriguez; Rosario Sanchez; Harry A Quigley; Ronald Klein; Robert Snyder; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-11       Impact factor: 4.799

5.  The psychosocial impact of macular degeneration.

Authors:  R A Williams; B L Brody; R G Thomas; R M Kaplan; S I Brown
Journal:  Arch Ophthalmol       Date:  1998-04

6.  Modeling valuations for EuroQol health states.

Authors:  P Dolan
Journal:  Med Care       Date:  1997-11       Impact factor: 2.983

7.  Assessment of vision-related function in patients with age-related macular degeneration.

Authors:  Paul J Mackenzie; Tom S Chang; Ingrid U Scott; Mark Linder; Dawn Hay; William J Feuer; Keith Chambers
Journal:  Ophthalmology       Date:  2002-04       Impact factor: 12.079

8.  TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD.

Authors:  Vinay A Shah; Shailesh K Gupta; Kanan V Shah; Sanjay Vinjamaram; K V Chalam
Journal:  Ophthalmic Epidemiol       Date:  2004-02       Impact factor: 1.648

9.  Functional status and quality of life measurement among ophthalmic patients.

Authors:  I U Scott; O D Schein; S West; K Bandeen-Roche; C Enger; M F Folstein
Journal:  Arch Ophthalmol       Date:  1994-03

10.  Health-related quality of life of cataract patients: cross-cultural comparisons of utility and psychometric measures.

Authors:  Jae Eun Lee; Peter J Fos; Miguel A Zuniga; Peter R Kastl; Jung Hye Sung
Journal:  Ophthalmic Epidemiol       Date:  2003-07       Impact factor: 1.648

View more
  13 in total

Review 1.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

2.  The impact of a belief in life after death on health-state preferences: True difference or artifact?

Authors:  Michał Jakubczyk; Dominik Golicki; Maciej Niewada
Journal:  Qual Life Res       Date:  2016-07-21       Impact factor: 4.147

3.  Nipple-areolar Complex Reconstruction following Postmastectomy Breast Reconstruction: A Comparative Utility Assessment Study.

Authors:  Ahmed M S Ibrahim; Hani H Sinno; Ali Izadpanah; Joshua Vorstenbosch; Tassos Dionisopoulos; Marc A M Mureau; Adam M Tobias; Bernard T Lee; Samuel J Lin
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-05-07

4.  Functional status mediates the association between peripheral neuropathy and health-related quality of life in individuals with diabetes.

Authors:  Tessa Riandini; Hwee Lin Wee; Eric Y H Khoo; Bee Choo Tai; Wilson Wang; Gerald C H Koh; E Shyong Tai; Subramaniam Tavintharan; Kurumbian Chandran; Siew Wai Hwang; Kavita Venkataraman
Journal:  Acta Diabetol       Date:  2017-11-28       Impact factor: 4.280

5.  Valuing health-related quality of life: systematic variation in health perception.

Authors:  Manuel Huber; Martin Vogelmann; Reiner Leidl
Journal:  Health Qual Life Outcomes       Date:  2018-08-02       Impact factor: 3.186

6.  Utility values for age-related macular degeneration patients in Korea.

Authors:  Seulggie Choi; Sang Min Park; Donghyun Jee
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

Review 7.  Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review.

Authors:  Xinyu Qian; Rachel Lee-Yin Tan; Ling-Hsiang Chuang; Nan Luo
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

8.  Cost-effectiveness of anti-oxidant vitamins plus zinc treatment to prevent the progression of intermediate age-related macular degeneration. A Singapore perspective.

Authors:  Nakul Saxena; Pradeep Paul George; Bee Hoon Heng; Tock Han Lim; Shao Onn Yong
Journal:  Indian J Ophthalmol       Date:  2015-06       Impact factor: 1.848

Review 9.  Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review.

Authors:  Edith Poku; John Brazier; Jill Carlton; Alberto Ferreira
Journal:  BMC Ophthalmol       Date:  2013-12-04       Impact factor: 2.209

10.  Disparities between Ophthalmologists and Patients in Estimating Quality of Life Associated with Diabetic Retinopathy.

Authors:  Xiaofeng Zhu; Qian Sun; Haidong Zou; Xun Xu; Xi Zhang
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.